Cat. No.: HY-136750

Z-LLY-FMK

(Synonyms: Calpain Inhibitor IV)

Customer Review

Based on 1 Customer Validation

Z-LLY-FMK (Calpain Inhibitor IV) is a calpain inhibitor, involved in apoptosis of many cell systems. Z-LLY-FMK inhibits the intestine apoptosis after common bile duct ligation. Z-LLY-FMK reduces parasite burden in mice challenged with Taenia crassiceps cysts. Z-LLY-FMK can be used for the study of cysticercosis.

For research use only. We do not sell to patients.

Purity: 98.65%
CAS No.: 133410-84-1
Formula: C₃₀H₄₀FN₃O₆
Molecular Weight:557.65

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Z-LLY-FMK Chemical Structure

CAS No.: 133410-84-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Calpain^[1]

All Parasite Isoforms :

In Vitro

Z-LLY-FMK (10 μM, 1 h pretreatment) inhibits Gal-9-induced apoptosis in MOLT-4 cells in a time- and dose-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Z-LLY-FMK (0.5 mg, via inferior vena cava immediately after common bile duct ligation, then 0.5 mg i.p. twice daily on days 1-2, and 0.5 mg i.p. on the morning of day 3) effectively diminishes hepatocyte apoptosis and ductular proliferation in common bile duct-ligated rats^[1].
Z-LLY-FMK (2.2 μg, i.p., daily, starting 2 days pre-infection and continuing for 30 days post-challenge) achieves an 80% reduction in parasite burden in BALB/c mice challenged with 10 Taenia crassiceps cysts^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Sprague-Dawley rats (250-300 g) underwent common bile duct ligation (double-ligated with 50 silk and divided between ligatures) to establish a model of extrahepatic cholestasis^[1].
Dosage:

0.5 mg
Administration:

0.5 mg via inferior vena cava immediately after common bile duct ligation, then 0.5 mg i.p. twice daily on days 1-2, and 0.5 mg i.p. on the morning of day 3
Result:

Significantly diminished hepatocyte apoptosis in common bile duct-ligated rats.
Markedly reduced ductular proliferation in common bile duct-ligated rats.

Animal Model:

Taenia crassiceps cysts (10 in 200 µL phosphate-buffered saline) were intraperitoneally challenged into BALB/c mice^[2]
Dosage:

2.2 μg
Administration:

i.p., daily starting 2 days pre-infection and continuing for 30 days post-challenge
Result:

Achieved an 80% reduction in parasite burden in BALB/c mice.
Showed no obvious toxicity.
Caused cysts to exhibit degenerative changes including tegumental erosion, shortened or sloughed microtriches, and breaks in the cyst surface.
Led to an intense but focal inflammatory reaction on cyst surfaces, with presence of fibroblasts, collagen, neutrophils, and macrophages.

Chemical Information

CAS No. 133410-84-1
Appearance Solid
Molecular Weight 557.65
Formula C₃₀H₄₀FN₃O₆
Color White to off-white
SMILES

O=C(CF)[C@@H](NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC(OCC1=CC=CC=C1)=O)=O)=O)CC(C=C2)=CC=C2O
Synonyms

Calpain Inhibitor IV
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (224.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7932 mL

8.9662 mL

17.9324 mL

5 mM

0.3586 mL

1.7932 mL

3.5865 mL

10 mM

0.1793 mL

0.8966 mL

1.7932 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Sheen-Chen SM, et al. Z-LLY-FMK can attenuate hepatocyte apoptosis after bile duct ligation in rat. Dig Dis Sci. 2008 Nov;53(11):2975-9. [Content Brief]

[2]. Baig S, et al. Cysteine proteinase inhibitors in murine cysticercosis. Antimicrob Agents Chemother. 2006 Aug;50(8):2886-8. [Content Brief]

[3]. Kashio Y, et al. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol. 2003 Apr 1;170(7):3631-6. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7932 mL	8.9662 mL	17.9324 mL	44.8310 mL
	5 mM	0.3586 mL	1.7932 mL	3.5865 mL	8.9662 mL
	10 mM	0.1793 mL	0.8966 mL	1.7932 mL	4.4831 mL
	15 mM	0.1195 mL	0.5977 mL	1.1955 mL	2.9887 mL
	20 mM	0.0897 mL	0.4483 mL	0.8966 mL	2.2415 mL
	25 mM	0.0717 mL	0.3586 mL	0.7173 mL	1.7932 mL
	30 mM	0.0598 mL	0.2989 mL	0.5977 mL	1.4944 mL
	40 mM	0.0448 mL	0.2242 mL	0.4483 mL	1.1208 mL
	50 mM	0.0359 mL	0.1793 mL	0.3586 mL	0.8966 mL
	60 mM	0.0299 mL	0.1494 mL	0.2989 mL	0.7472 mL
	80 mM	0.0224 mL	0.1121 mL	0.2242 mL	0.5604 mL
	100 mM	0.0179 mL	0.0897 mL	0.1793 mL	0.4483 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Z-LLY-FMK

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

Apoptosis Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Ubiquitination Compound Library

Anti-Blood Cancer Compound Library

Antiparasitic Compound library

Protease Inhibitor Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

All Parasite Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Z-LLY-FMK

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

Apoptosis Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Ubiquitination Compound Library

Anti-Blood Cancer Compound Library

Antiparasitic Compound library

Protease Inhibitor Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

All Parasite Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Z-LLY-FMK Related Classifications

HY-136750 Related Classifications